Sugi Predict

Sugi Predict / Compounds / SCHEMBL2060435

SCHEMBL2060435

SCHEMBL2060435

Nc1ccccc1C(=O)NC1CC1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CRBN Q96SW2 1/20 0.56
▸ ALDH1A1 P00352 4/20 0.56
▸ NPC1 O15118 4/20 0.56
▸ RAB9A P51151 4/20 0.56
▸ KDM4E B2RXH2 3/20 0.56
▸ HPGD P15428 3/20 0.56
▸ LMNA P02545 2/20 0.56
▸ P2RX7 Q99572 1/20 0.56
▸ HTT P42858 1/20 0.56
▸ GAA P10253 3/20 0.53
▸ MEN1 O00255 2/20 0.51
▸ KMT2A Q03164 2/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.51
▸ MAPT P10636 2/20 0.51
▸ NPSR1 Q6W5P4 1/20 0.51
▸ PKM P14618 1/20 0.51
▸ SMYD3 Q9H7B4 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL28110279 0.98 CRBN (0.55) CRBNALDH1A1NPC1RAB9AKDM4E
SCHEMBL28510668 0.93 CRBN (0.51) CRBNALDH1A1NPC1RAB9AKDM4E
SCHEMBL2771766 0.93 CRBN (0.51) CRBNALDH1A1NPC1RAB9AKDM4E
SCHEMBL4960760 0.93 NPC1 (0.53) CRBNALDH1A1NPC1RAB9AKDM4E
SCHEMBL2771765 0.93 CRBN (0.51) CRBNALDH1A1NPC1RAB9AKDM4E
SCHEMBL22720116 0.93 ALDH1A1 (0.66) CRBNALDH1A1NPC1RAB9AKDM4E
SCHEMBL13161898 0.93 ALDH1A1 (0.61) CRBNALDH1A1NPC1RAB9AKDM4E
SCHEMBL13634186 0.92 RAB9A (0.59) CRBNALDH1A1NPC1RAB9AKDM4E
SCHEMBL22720137 0.92 RAB9A (0.59) CRBNALDH1A1NPC1RAB9AKDM4E
SCHEMBL2154833 0.91 ALDH1A1 (0.69) ALDH1A1NPC1RAB9AKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4622964-A1 QUINAZOLINONE DERIVATIVES FOR HDAC INHIBITION Gilva Therapeutics Co., Ltd. (TW) 2025-10-01 — — EP disclosed
WO-2025085669-A1 QUINAZOLINONE DERIVATIVES FOR HDAC INHIBITION GILVA THERAPEUTICS CO., LTD. (CN) 2025-04-24 — — WO disclosed
CN-119462526-A Method for synthesizing quinazolinone compound by catalytic cyclization of titanocene dichloride 陕西师范大学 2025-02-18 — — CN disclosed
CN-114276203-B Method for synthesizing 2-aminobenzamide compound by ultraviolet light induction 湖南大学 2023-03-31 — — CN disclosed
CN-114276203-A Method for synthesizing 2-aminobenzamide compound by ultraviolet light induction 湖南大学 2022-04-05 — — CN disclosed
CN-107793363-B Substituted arylamino aromatic heterocyclic compound and application thereof as antitumor drug 上海医药工业研究院 2021-02-26 — — CN disclosed
WO-2020239050-A1 2-(2-CHLORO-4-METHYLPHENYL)QUINAZOLINE-4(3H)-KETONE COMPOUND AND MEDICAL USE THEREOF 中国人民解放军军事科学院军事医学研究院 2020-12-03 — — WO disclosed
CN-111943878-A Benzo beta-lactam and preparation method thereof 兰州交通大学 2020-11-17 — — CN disclosed
CN-110041272-B 2- (2-chlorphenyl) quinazoline-4 (3H) -ketone derivative and preparation method and application thereof 中国人民解放军军事科学院军事医学研究院 2020-10-30 — — CN disclosed
CN-110041273-B 2- (2-chloro-4-methylphenyl) quinazoline-4 (3H) -ketone compound and medical application thereof 中国人民解放军军事科学院军事医学研究院 2020-10-20 — — CN disclosed
WO-2007120339-A1 PYRIMIDINE KINASE INHIBITORS GENENTECH, INC. (US) 2007-10-25 — — WO disclosed
WO-2007120339-A1 PYRIMIDINE KINASE INHIBITORS GENENTECH, INC. (US) 2007-10-25 — — WO disclosed
US-6919331-B2 Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents BRISTOL-MYERS SQUIBB COMPANY (US) 2005-07-19 — — US disclosed
US-6884801-B1 Imidazoline derivatives as alpha-1A adrenoceptor ligands SMITHKLINE BEECHAM CORPORATION (US) 2005-04-26 — — US disclosed
EP-1461035-A4 SUBSTITUTED 2-METHYL-BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS BRISTOL MYERS SQUIBB CO (US) 2005-04-06 — — EP disclosed
EP-1461035-A2 SUBSTITUTED 2-METHYL-BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS Bristol-Myers Squibb Company (US) 2004-09-29 — — EP disclosed
US-20030207868-A1 Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents BRISTOL-MYERS SQUIBB COMPANY 2003-11-06 — — US disclosed
WO-2003053344-A2 SUBSTITUTED 2-METHYL-BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-07-03 — — WO disclosed
EP-1175406-A1 IMIDAZOLINE DERIVATIVES AS ALPHA-1A ADRENOCEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2002-01-30 — — EP disclosed
WO-2000066563-A1 IMIDAZOLINE DERIVATIVES AS ALPHA-1A ADRENOCEPTOR LIGANDS GLAXO GROUP LIMITED (GB) 2000-11-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207868-A1 Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents MAVS, ZC3HAV1, EIF2AK2 CRBN 996/4885ALDH1A1 3132/4885NPC1 2148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.